HansBiomed Corporation - Asset Resilience Ratio
HansBiomed Corporation (042520) has an Asset Resilience Ratio of 9.13% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 042520 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how HansBiomed Corporation's Asset Resilience Ratio has changed over time. See HansBiomed Corporation (042520) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down HansBiomed Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 042520 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩11.75 Billion | 9.13% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩11.75 Billion | 9.13% |
Asset Resilience Insights
- Limited Liquidity: HansBiomed Corporation maintains only 9.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
HansBiomed Corporation Industry Peers by Asset Resilience Ratio
Compare HansBiomed Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for HansBiomed Corporation (2012–2023)
The table below shows the annual Asset Resilience Ratio data for HansBiomed Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-09-30 | 0.75% | ₩916.26 Million ≈ $620.93K |
₩122.37 Billion ≈ $82.93 Million |
-10.63pp |
| 2022-09-30 | 11.38% | ₩14.98 Billion ≈ $10.15 Million |
₩131.69 Billion ≈ $89.24 Million |
-4.28pp |
| 2021-09-30 | 15.66% | ₩20.27 Billion ≈ $13.74 Million |
₩129.44 Billion ≈ $87.72 Million |
-2.22pp |
| 2020-09-30 | 17.88% | ₩23.57 Billion ≈ $15.97 Million |
₩131.81 Billion ≈ $89.32 Million |
+10.12pp |
| 2019-09-30 | 7.76% | ₩10.40 Billion ≈ $7.05 Million |
₩134.09 Billion ≈ $90.87 Million |
-1.68pp |
| 2018-09-30 | 9.44% | ₩8.66 Billion ≈ $5.87 Million |
₩91.80 Billion ≈ $62.21 Million |
+3.53pp |
| 2017-09-30 | 5.90% | ₩4.73 Billion ≈ $3.21 Million |
₩80.19 Billion ≈ $54.34 Million |
+2.61pp |
| 2016-09-30 | 3.29% | ₩2.13 Billion ≈ $1.44 Million |
₩64.72 Billion ≈ $43.86 Million |
+3.27pp |
| 2015-09-30 | 0.02% | ₩9.04 Million ≈ $6.13K |
₩52.11 Billion ≈ $35.32 Million |
-0.13pp |
| 2014-09-30 | 0.15% | ₩67.25 Million ≈ $45.58K |
₩44.34 Billion ≈ $30.05 Million |
-0.09pp |
| 2013-09-30 | 0.25% | ₩81.89 Million ≈ $55.50K |
₩33.36 Billion ≈ $22.61 Million |
-15.68pp |
| 2012-09-30 | 15.92% | ₩4.31 Billion ≈ $2.92 Million |
₩27.05 Billion ≈ $18.33 Million |
-- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more